Figure 4.
Tyrosine hydroxylase and OX-42 immunoreactivity measured in the substantia nigra of rats injected i.c.v. with 6-hydroxydopamine or saline (control rats) and subjected to chronic i.p. treatment with Δ9-THCV (2 mg·kg−1; 14 days), CBD-enriched botanical extract (4.63 mg·kg−1, equivalent to 3 mg·kg−1 of pure CBD; 14 days) or vehicle, starting 16 h after the i.c.v. injection. Values are means ± SEM (n = 5–6 rats per group), and the data were subjected to one-way anova followed by the Student–Newman–Keuls test (*P < 0.05, **P < 0.005, ***P < 0.0005 vs. controls; #P < 0.05 vs. 6-hydroxydopamine-lesioned animals). Representative tyrosine hydroxylase- and OX-42-immunostained sections of the substantia nigra are shown for the four experimental groups in the lower panels (scale bar = 100 µm for tyrosine hydroxylase and 50 µm for OX-42). Tyrosine hydroxylase– and OX-42-positive cells are indicated with arrows.